Amylyx CEO Joshua Cohen Receives Award of 60,039 Shares

What Happened Joshua B. Cohen, Chief Executive Officer of Amylyx Pharmaceuticals (AMLX), was awarded 60,039 shares that vested on August 18, 2026. The transaction is reported as an award/grant (transaction code A) with an acquisition price of $0.00 (no cash paid). The Form 4 was filed on August 20, 2026.

Key Details

• Transaction date: August 18, 2026; Form 4 filed: August 20, 2026 (appears timely under the 2‑business‑day rule).
• Shares awarded/acquired: 60,039 common shares; reported acquisition price: $0.00 (total cash paid $0).
• Transaction code: A (award/grant). Footnote: these shares were issued upon vesting of performance share units (PSUs) tied to performance metrics.
• Shares owned after transaction: not specified in the summary provided here — see the filed Form 4 for post‑transaction holdings.
• No indication of tax withholding, sale, or 10b5‑1 plan in the supplied details.

Context This was an equity compensation vesting (PSUs converting to shares), not an open‑market purchase or sale. Such awards reflect executive compensation tied to company performance and do not, by themselves, indicate a personal buy/sell decision or direct market sentiment. For complete ownership totals and any tax‑related share withholding, review the full Form 4 filed with the SEC (Accession No. 0001193125-26-359675).